Sunshine Biopharma, Inc. (SBFM) Total Debt to Capital

Sunshine Biopharma - graphic logo of issuer SBFM

Sunshine Biopharma (SBFM) possesses authority in creating targeted agents against tumors and viruses. The quotes provided below demonstrate a debt-to-equity ratio of 0.02. The business relies on promising mRNA technologies for liver therapy and the development of oral medications, counting on future license sales to industry behemoths to scale its innovations.

sunshinebiopharma.com (SBFM): Debt to Equity Ratio from 07/04/2022 to 10/30/2026

Metric breakdowns and analytics for sunshinebiopharma.com (SBFM)

- share price and consensus valuation forecast:
Stock Price Sunshine Biopharma|SBFM - Consensus Target
- market capitalization details:
Market Capitalization Sunshine Biopharma|SBFM - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share Sunshine Biopharma|SBFM - Accounting Capitalization|Market Capitalization to Book Value Ratio sunshinebiopharma.com|SBFM - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital Sunshine Biopharma|SBFM - Long-Term Liabilities to Capital|Short-Term Debt to Equity Sunshine Biopharma, Inc.|SBFM - Aggregate Debt Obligations|Debt to Book Value Sunshine Biopharma|SBFM - Company Long-Term Loans and Borrowings|Company Short-Term Debts Sunshine Biopharma|Quick Liquidity Indicator sunshinebiopharma.com
- net income and valuation ratios data:
SBFM - Net Profit
Fundamental company valuation:Sunshine Biopharma
Finished products of Sunshine Biopharma, Inc.

When constructing a long-term portfolio, it is critical to evaluate financial leverage to eliminate the risk of bankruptcy during market shocks. This indicator measures the proportion of borrowed funds within the asset structure relative to equity, which for Sunshine Biopharma (SBFM) determines the ability to fund KAb-201 development and patent protection without critical dependence on creditors, reflecting this through the total debt-to-equity ratio.

Competitor analysis for Sunshine Biopharma

ONC (BeiGene) - Total Debt to Capital|Total Debt to Equity Ratio Halozyme Therapeutics, Inc. (HALO)|Total Debt to Capital RVMD|Total Debt to Capital Ascentage Pharma Corp (AAPG)|Debt to Equity CG Oncology, Inc. CGON|URGN: Debt to Equity Ratio|Bicara Therapeutics - Total Debt to Capital|Personalis Inc (PSNL) - Total Debt to Equity Ratio|ERAS: Total Debt to Capital|Debt to Capital Delcath Corp (DCTH)|Debt to Equity Y-mAbs Therapeutics|AURA: All Debt to Shareholders' Equity Ratio|Total Debt to Equity Ratio CADL (Candel Therapeutics)|ARAY (Accuray Inc) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital SLS (SELLAS Life Sciences Group)|ACTU - Total Debt to Equity Ratio|CTOR: Total Debt to Equity Ratio|HURA - Total Debt to Capital|Protara Therapeutics, Inc. (TARA) - Debt to Equity|Fate Therapeutics Inc - All Debt to Shareholders' Equity Ratio|WHWK (Aadi Bioscience, Inc.) - Total Debt to Capital|Debt to Capital TScan TCRX|Debt to Equity Champions Oncology (CSBR)|Total Debt to Capital Coefficient xbiotech.com|CEL-SCI - Total Debt to Equity Ratio|Total Debt to Capital OS Therapies Inc. OSTX|RADX - Debt to Equity|ARTV (Artiva Biotherapeutics, Inc.) - Debt to Equity Ratio|adlainortye.com (ANL) - Debt to Equity|VERU - Total Debt to Capital Coefficient|TPST (Tempest Therapeutics, Inc.) - Total Debt to Capital|XLO: All Debt to Shareholders' Equity Ratio|Total Debt to Capital RENB|Total Debt to Capital Coefficient muraloncology.com|Debt to Equity Kairos Pharma KAPA|OKUR: Debt to Equity Ratio|CytoMed - Total Debt to Capital|Debt to Capital Curis, Inc.|APLM (apollomicsinc.com) - Total Debt to Equity Ratio|Tharimmune Corporation - All Debt to Shareholders' Equity Ratio|ADVB (Advanced Biomed Inc.) - Total Debt to Capital|Debt to Equity GNPX|Total Debt to Capital CLDI|Total Debt to Capital Coefficient xeneticbio.com|Debt to Equity Salarius SLRX|Kitov Pharma (PPBT) - Debt to Capital|AONC - Debt to Equity|Aggregate Debt to Equity BGNE|CKPT: Total Debt to Capital|elevationoncology.com - All Debt to Shareholders' Equity Ratio|ICAD (iCAD Inc.) - Total Debt to Capital|Total Debt to Capital Ikena|Debt to Equity Notable Labs, Ltd. (NTBL)|VIRX (viracta.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity MorphoSys MOR|NAYA - Total Debt to Equity Ratio|Ascentage Pharma Group Ltd - Total Debt to Capital